公开(公告)号：US10736845B2

公开(公告)日：2020-08-11

申请号：US15059943

申请日：2016-03-03

Applicant: Cureport, Inc.

Inventor： De-Min Zhu ,  Guoqiang Chen

IPC: A61K9/127 ,  A61K9/00 ,  A61K31/337 ,  A61K31/704

Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.

公开(公告)号：US20180000735A1

公开(公告)日：2018-01-04

申请号：US15623983

申请日：2017-06-15

Applicant: Cureport, Inc.

Inventor： De-Min Zhu

IPC: A61K9/127 ,  A61K31/704 ,  A61K9/51 ,  C12N15/113

CPC classification number: A61K9/1277 ,  A61K9/5192 ,  A61K31/704 ,  C12N15/113 ,  Y10S977/773 ,  Y10S977/907

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

公开(公告)号：US20140348900A1

公开(公告)日：2014-11-27

申请号：US14209187

申请日：2014-03-13

Applicant: Cureport, Inc.

Inventor： De-Min Zhu

IPC: A61K9/127 ,  C12N15/113 ,  A61K31/704

CPC classification number: A61K9/1277 ,  A61K9/5192 ,  A61K31/704 ,  C12N15/113 ,  Y10S977/773 ,  Y10S977/907

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

Abstract translation: 本发明提供使用多端口歧管制备脂质体，脂质盘和其它脂质纳米颗粒的方法，其中将含有有机溶剂的脂质溶液流与两种或更多种水溶液（例如缓冲液）混合 ）。 在一些方面，脂质和水溶液的至少一些流不彼此直接相对。 因此，该方法不需要稀释有机溶剂作为附加步骤。 在一些实施方案中，一种溶液也可含有活性药物成分（API）。 本发明提供了具有不同脂质制剂和不同有效载荷的脂质体制造的可靠工艺。 可以通过改变端口尺寸和歧管端口数量以及选择脂质和水溶液的流速或流速来控制粒度，形态和制造规模。

公开(公告)号：US20240299312A1

公开(公告)日：2024-09-12

申请号：US18023564

申请日：2023-02-24

Applicant: Cureport Inc.

Inventor： De-Min Zhu

IPC: A61K9/51 ,  A61K31/7105 ,  A61K31/711 ,  C12N15/88

CPC classification number: A61K9/5146 ,  A61K9/5123 ,  A61K9/5192 ,  A61K31/7105 ,  A61K31/711 ,  C12N15/88

Abstract: Disclosed herein are nanoparticle compositions including a polymer component and a lipid component. The disclosure also relates to lipid nanoparticles (LNPs) having the nanoparticle composition for nucleic acid delivery, and methods of making and using the same. The LNPs can be used for fast, efficient and safe delivery of nucleic acid (e.g., DNA/RNA).

公开(公告)号：US11497715B2

公开(公告)日：2022-11-15

申请号：US15623983

申请日：2017-06-15

Applicant: Cureport, Inc.

Inventor： De-Min Zhu

IPC: A61K9/127 ,  A61K9/51 ,  C12N15/113 ,  A61K31/704

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

公开(公告)号：US09693958B2

公开(公告)日：2017-07-04

申请号：US14209187

申请日：2014-03-13

Applicant: Cureport, Inc.

Inventor： De-Min Zhu

IPC: A61K9/127 ,  A61K31/704 ,  C12N15/113 ,  A61K9/51

CPC classification number: A61K9/1277 ,  A61K9/5192 ,  A61K31/704 ,  C12N15/113 ,  Y10S977/773 ,  Y10S977/907

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.